Mundipharma aims to improve the health and quality of life of patients everywhere with innovative products that meet their needs and the needs of the health care professionals. Mundipharma’s cancer treatment and cancer supportive care portfolio includes products for treating neuro-oncological and haematological malignancies, managing chemotherapy induced nausea and vomiting and cancer anorexia – cachexia.
||Pralatrexate Solution for intravenous injection
||Netupitant and Palonosetron capsules
||Palonosetron capsules / solution for injection
||Ibritumomab Tiuxetan Intravenous Injection
THE PRODUCT RANGE INCLUDES:
FolotynTM (pralatraxate), a folate analogue metabolic inhibitor, is the first FDA approved drug for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a biologically diverse group of aggressive blood cancers.
DepocyteTM (liposomal cytarabine) – A sustained-release injectable formulation of cytarabine for the treatment of lymphomatous meningitis, a serious late-stage complication of lymphoma.
Aloxi® (Palonosetron) is a 5-HT3 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is available in i.v. formulation. It is indicated for prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy in adults.
Akynzeo® – An oral combination of netupitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)1
Zevalin® – a CD20-directed radiolabeled antibody injection (to be administered after rituximab).
FolotynTM & Depocyte™ are trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.
Akynzeo® and Aloxi® are registered trademarks in UAE and are trademarks or registered trademarks in other countries, of Helsinn Healthcare SA, Switzerland, used under license.
Zevalin® is a registered trademark of Bayer Schering Pharma AG in UAE and is a trademark or registered trademark in other countries.
Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities
* Not all products or indications are available in all countries. Products are currently under registrations across Middle East, Turkey and Africa Region and subject to approval according to local laws and regulations.
Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.